Michael Lukesch, VALANX Biotech GmbH
Small differences in where a payload is attached to an antibody can create big differences in the resulting antibody-drug-conjugate. This affects stability, aggregation, efficacy and tolerability. Yet conjugation site selection is still frequently constrained by legacy formats or evaluated late, after costly development steps. In this presentation we introduce GoldenSite, a technology that enables systematic exploration of conjugation sites and couples it to high-throughput biophysical assay services to rapidly find sites that produce better drug-like molecules.